Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2012

01-03-2012 | Original Article

The impact of teriparatide adherence and persistence on fracture outcomes

Authors: S. Yu, R. T. Burge, S. A. Foster, S. Gelwicks, E. S. Meadows

Published in: Osteoporosis International | Issue 3/2012

Login to get access

Abstract

Summary

The study investigated the real-world relationship between teriparatide adherence and persistence and fracture outcomes in a US claims database. Fracture risk was estimated to decrease as adherence and persistence increased for any clinical, vertebral, and non-vertebral fractures. Greater emphasis on programs to increase patient adherence may improve clinical outcomes.

Introduction

Adherence to osteoporosis treatment is essential for achieving optimal therapeutic outcomes. Previous findings from clinical trials and observational studies demonstrate that longer teriparatide (TPTD) exposure is associated with fewer fractures. The study aim was to investigate real-world relationships between TPTD adherence and persistence and fracture outcomes.

Methods

The Thomson Reuters MarketScan® database, 2004–2008, was used to identify TPTD users with continuous enrollment 12 months pre- and 24 months post-TPTD initiation. Post-index fractures included vertebral and non-vertebral. Adherence (medication possession ratio, MPR) groups were defined as high (MPR ≥ 0.80), medium (0.5 ≤ MPR < 0.8), and low (MPR < 0.5). Persistence groups were defined by periods 1–6, 7–12, 13–18, and 19–24 months. Logistic regressions modeled fracture risk for any clinical, hip, vertebral, and non-vertebral fractures, controlling for patient characteristics, insurance and healthcare provider types, Charlson comorbidity index, bone mineral density screening, medication use, and fracture history.

Results

Among 3,587 TPTD patients (mean age 68.9 years; 91% female), fracture risk was lowest in high MPR patients in all models except hip (OR = 1.17; p = 0.64). Medium versus high MPR was a significant risk factor for any fracture (OR = 1.49; p = 0.004) and non-vertebral fracture (OR = 1.45; p = 0.014); low-MPR was a significant risk factor for any fracture (OR = 1.64; p < 0.01), vertebral fracture (OR = 2.56; p = 0.001), and non-vertebral fracture (OR = 1.44; p = 0.013). Persistence of 1–6 months versus 19–24 months was associated with higher risk for any clinical (OR = 1.88, p < 0.001), vertebral (OR = 3.69; p < 0.001), and non-vertebral fracture (OR = 1.51; p = 0.011), but not hip (OR = 1.93; p = 0.08).

Conclusions

Fracture risk decreased as TPTD adherence and persistence increased for any clinical, vertebral, and non-vertebral fractures.
Appendix
Available only for authorised users
Literature
1.
US Department of Health and Human Services, Office of the Surgeon General (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General, Rockville
2.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785–795CrossRef
3.
Burge R, Dawson-Hughes B, Solomon DH et al (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRef
4.
5.
Seeman E, Compston J, Adachi J et al (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18:711–719PubMedCrossRef
6.
Siris E, Selby P, Saag KG, Borgström F, Herings R, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13PubMedCrossRef
7.
Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef
8.
Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517PubMedCrossRef
9.
Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271–277PubMedCrossRef
10.
Halpern R, Becker L, Usman Iqbal S, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17:25–39PubMed
11.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef
12.
Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575PubMedCrossRef
13.
Lindsay R, Miller P, Pohl G, Glass E, Chen P, Krege JH (2009) Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 20:943–948PubMedCrossRef
14.
Silverman, SL, Miller P, Sebba AI, Weitz M, Wan X, Taylor K, Ruff V (2010) The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. [abstract]. Arthritis Rheum 62 Suppl 10:980. doi:10.​1002/​art.​28747
15.
Langdahl B, Rajzbaum G, Jacob F et al (2009) Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 85:484–493PubMedCrossRef
16.
Foster SA, Foley KA, Meadows ES et al (2008) Characteristics of patients initiating teriparatide for the treatment of osteoporosis. Osteoporos Int 19:373–377PubMedCrossRef
17.
Foster SA, Foley KA, Meadows ES et al (2011) Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 22:551–557PubMedCrossRef
18.
Lee RH, Lyles KW, Colon-Emerec C (2010) A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. J Am Ger Soc 8:34–46
19.
Petty SJ, O'Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporos Int 18:129–142PubMedCrossRef
20.
Black DM, Reiss T, Nevitt MC et al (1993) Design of the Fracture Intervention Trial. Osteoporos Int 3(suppl 3):S29–S39PubMedCrossRef
21.
Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:1–10CrossRef
22.
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340PubMedCrossRef
23.
Ross S, Samuels E, Gairy K et al (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571–581PubMedCrossRef
24.
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
25.
Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F et al (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22:2709–2719PubMedCrossRef
Metadata
Title
The impact of teriparatide adherence and persistence on fracture outcomes
Authors
S. Yu
R. T. Burge
S. A. Foster
S. Gelwicks
E. S. Meadows
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1843-3

Other articles of this Issue 3/2012

Osteoporosis International 3/2012 Go to the issue

Original Article

Treatment for older men with fractures

Original Article

Premature T cell senescence in Ovx mice is inhibited by repletion of estrogen and medicarpin: a possible mechanism for alleviating bone loss

Original Article

Association of spinal curve deformity and back extensor strength in elderly women with osteoporosis in Japan and the United States

Original Article

Undertreatment of osteoporosis in persons with dementia? A population-based study

Original Article

Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008

Original Article

Adiposity and bone health in Spanish adolescents. The HELENA study